Access the full text.
Sign up today, get DeepDyve free for 14 days.
K. Hoang-Xuan, L. Capelle, M. Kujas, S. Taillibert, H. Duffau, J. Lejeune, M. Polivka, E. Crinière, Y. Marie, K. Mokhtari, A. Carpentier, F. Laigle, J. Simon, P. Cornu, P. Broët, M. Sanson, J. Delattre (2004)
Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 22 15
K. Kono, Y. Inoue, K. Nakayama, M. Shakudo, M. Morino, K. Ohata, K. Wakasa, R. Yamada (2001)
The role of diffusion-weighted imaging in patients with brain tumors.AJNR. American journal of neuroradiology, 22 6
C. Houillier, Xiao-wei Wang, G. Kaloshi, K. Mokhtari, R. Guillevin, J. Laffaire, S. Paris, B. Boisselier, A. Idbaih, F. Laigle-Donadey, K. Hoang-Xuan, M. Sanson, J. Delattre (2010)
IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomasNeurology, 75
S. Higano, Xia Yun, T. Kumabe, Mika Watanabe, S. Mugikura, A. Umetsu, A. Sato, Takayuki Yamada, Shoki Takahashi (2006)
Malignant astrocytic tumors: clinical importance of apparent diffusion coefficient in prediction of grade and prognosis.Radiology, 241 3
R. Stupp, Warren Mason, M. Bent, M. Weller, B. Fisher, M. Taphoorn, K. Bélanger, A. Brandes, C. Marosi, U. Bogdahn, J. Curschmann, Robert Janzer, Samuel Ludwin, T. Gorlia, A. Allgeier, D. Lacombe, J. Cairncross, E. Eisenhauer, R. Mirimanoff (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.The New England journal of medicine, 352 10
S. Fellah, D. Caudal, A. Paula, P. Dory-Lautrec, D. Figarella-Branger, O. Chinot, P. Metellus, P. Cozzone, S. Confort-Gouny, B. Ghattas, V. Callot, N. Girard (2013)
Multimodal MR Imaging (Diffusion, Perfusion, and Spectroscopy): Is It Possible to Distinguish Oligodendroglial Tumor Grade and 1p/19q Codeletion in the Pretherapeutic Diagnosis?American Journal of Neuroradiology, 34
R. Murakami, T. Sugahara, Hideo Nakamura, T. Hirai, M. Kitajima, Y. Hayashida, Y. Baba, N. Oya, J. Kuratsu, Y. Yamashita (2007)
Malignant supratentorial astrocytoma treated with postoperative radiation therapy: prognostic value of pretreatment quantitative diffusion-weighted MR imaging.Radiology, 243 2
M Zulfiqar, DM Yousem, H Lai (2013)
ADC values and prognosis of malignant astrocytomas: does lower ADC predict a worse prognosis independent of grade of tumor?–a meta-analysisAm J Roentgenol, 200
P. Ambros, I. Ambros (2001)
Pathology and biology guidelines for resectable and unresectable neuroblastic tumors and bone marrow examination guidelines.Medical and pediatric oncology, 37 6
N. Kokshoorn, J. Tiemensma, F. Roelfsema (2011)
multi-center study.
M. Hegi, A. Diserens, Sophie Godard, P. Dietrich, L. Regli, Sandrine Ostermann, Philippe Otten, G. Melle, N. Tribolet, R. Stupp (2004)
Clinical Trial Substantiates the Predictive Value of O-6-Methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastoma Patients Treated with TemozolomideClinical Cancer Research, 10
National Comprehensive Cancer Network (2013) NCCN Guidelines Ò updates
T. Chenevert, L. Stegman, J. Taylor, P. Robertson, H. Greenberg, A. Rehemtulla, B. Ross (2000)
Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors.Journal of the National Cancer Institute, 92 24
Y. Ino, R. Betensky, M. Zlatescu, H. Sasaki, D. MacDonald, A. Stemmer-Rachamimov, D. Ramsay, J. Cairncross, D. Louis (2001)
Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis.Clinical cancer research : an official journal of the American Association for Cancer Research, 7 4
M. Zulfiqar, D. Yousem, H. Lai (2013)
ADC values and prognosis of malignant astrocytomas: does lower ADC predict a worse prognosis independent of grade of tumor?--a meta-analysis.AJR. American journal of roentgenology, 200 3
B. Ellingson, M. Malkin, S. Rand, J. Connelly, C. Quinsey, P. LaViolette, D. Bedekar, K. Schmainda (2010)
Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularityJournal of Magnetic Resonance Imaging, 31
Gisele Caseiras, O. Ciccarelli, D. Altmann, C. Benton, D. Tozer, P. Tofts, T. Yousry, J. Rees, A. Waldman, H. Jäger (2009)
Low-grade gliomas: six-month tumor growth predicts patient outcome better than admission tumor volume, relative cerebral blood volume, and apparent diffusion coefficient.Radiology, 253 2
(2013)
NCCN Guidelines updates
Rakesh Gupta, T. Cloughesy, U. Sinha, Justine Garakian, J. Lazareff, G. Rubino, Lisa Rubino, D. Becker, H. Vinters, J. Alger (2000)
Relationships Between Choline Magnetic Resonance Spectroscopy, Apparent Diffusion Coefficient and Quantitative Histopathology in Human GliomaJournal of Neuro-Oncology, 50
Inas Khayal, S. Vandenberg, Kenneth Smith, C. Cloyd, Susan Chang, S. Cha, S. Nelson, T. Mcknight (2011)
MRI apparent diffusion coefficient reflects histopathologic subtype, axonal disruption, and tumor fraction in diffuse-type grade II gliomas.Neuro-oncology, 13 11
Forrest Crawford, Inas Khayal, Colleen McGue, S. Saraswathy, A. Pirzkall, S. Cha, K. Lamborn, Susan Chang, M. Berger, S. Nelson (2009)
Relationship of pre-surgery metabolic and physiological MR imaging parameters to survival for patients with untreated GBMJournal of Neuro-Oncology, 91
F. Pignatti, M. Bent, D. Curran, C. Debruyne, R. Sylvester, P. Therasse, D. Áfra, P. Cornu, M. Bolla, C. Vecht, A. Karim (2002)
Prognostic factors for survival in adult patients with cerebral low-grade glioma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 20 8
D. Hamstra, C. Galbán, C. Meyer, T. Johnson, P. Sundgren, C. Tsien, T. Lawrence, L. Junck, David Ross, A. Rehemtulla, B. Ross, T. Chenevert (2008)
Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 20
P. Brastianos, W. Curry, K. Oh (2013)
Clinical discussion and review of the management of brain metastases.Journal of the National Comprehensive Cancer Network : JNCCN, 11 9
G. Kaloshi, A. Benouaich‐Amiel, F. Diakité, S. Taillibert, J. Lejeune, F. Laigle-Donadey, Maxime Renard, W. Iraqi, A. Idbaih, S. Paris, L. Capelle, H. Duffau, P. Cornu, Jeremy Simon, K. Mokhtari, M. Polivka, A. Omuro, A. Carpentier, M. Sanson, J. Delattre, K. Hoang-Xuan (2011)
Temozolomide for low-grade gliomas: Predictive impact of 1p/19q loss on response and outcomeNeurology, 77
X. Ren, Xiang-li Cui, Song Lin, Junmei Wang, Zhongli Jiang, D. Sui, Jing Li, Zhong-cheng Wang (2012)
Co-Deletion of Chromosome 1p/19q and IDH1/2 Mutation in Glioma Subsets of Brain Tumors in Chinese PatientsPLoS ONE, 7
M. Sanson, Y. Marie, S. Paris, A. Idbaih, J. Laffaire, F. Ducray, S. Hallani, B. Boisselier, K. Mokhtari, K. Hoang-Xuan, J. Delattre (2009)
Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 25
T. Sugahara, Y. Korogi, M. Kochi, I. Ikushima, Y. Shigematu, T. Hirai, T. Okuda, L. Liang, Y. Ge, Y. Komohara, Yukitaka Ushio, Mutsumasa Takahashi (1999)
Usefulness of diffusion‐weighted MRI with echo‐planar technique in the evaluation of cellularity in gliomasJournal of Magnetic Resonance Imaging, 9
K Kono, Y Inoue, K Nakayama, M Shakudo, M Morino, K Ohata, K Wakasa, R Yamada (2001)
The role of diffusion-weighted imaging in patients with brain tumorsAm J Neuroradiol, 22
D. Louis, H. Ohgaki, O. Wiestler, W. Cavenee, P. Burger, A. Jouvet, B. Scheithauer, P. Kleihues (2007)
The 2007 WHO Classification of Tumours of the Central Nervous SystemActa Neuropathologica, 114
W. Pope, Xin Qiao, Hyun Kim, A. Lai, P. Nghiemphu, X. Xue, B. Ellingson, D. Schiff, D. Aregawi, S. Cha, V. Puduvalli, Jing Wu, W. Yung, G. Young, J. Vredenburgh, D. Barboriak, L. Abrey, T. Mikkelsen, R. Jain, N. Paleologos, P. Rn, M. Prados, J. Goldin, P. Wen, T. Cloughesy (2012)
Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center studyJournal of Neuro-Oncology, 108
F. Yamasaki, K. Sugiyama, M. Ohtaki, Y. Takeshima, N. Abe, Y. Akiyama, J. Takaba, V. Amatya, T. Saito, Y. Kajiwara, R. Hanaya, K. Kurisu (2010)
Glioblastoma treated with postoperative radio-chemotherapy: prognostic value of apparent diffusion coefficient at MR imaging.European journal of radiology, 73 3
Haihui Jiang, X. Ren, Wei Zhang, Jun Ma, D. Sui, Zhongli Jiang, Xiang-li Cui, Song Lin (2013)
A new prognostic scoring scale for patients with primary WHO grade III gliomas based on molecular predictorsJournal of Neuro-Oncology, 111
M. Bent, O. Chinot, J. Cairncross (2003)
Recent developments in the molecular characterization and treatment of oligodendroglial tumors.Neuro-oncology, 5 2
Richard Theriault, Robert Carlson, C. Allred, B. Anderson, H. Burstein, Stephen Edge, William Farrar, A. Forero, Sharon Giordano, Lori Goldstein, W. Gradishar, Daniel Hayes, Cliff Hudis, S. Isakoff, B. Ljung, D. Mankoff, P. Marcom, I. Mayer, B. McCormick, Lori Pierce, Elizabeth Reed, L. Schwartzberg, Mary Smith, H. Soliman, G. Somlo, John Ward, A. Wolff, R. Zellars, Dorothy Shead, Rashmi Kumar (2013)
Breast Cancer, Version 3.2013Journal of The National Comprehensive Cancer Network, 11
T. Daniels, P. Brown, Sara Felten, Wenting Wu, J. Buckner, R. Arusell, W. Curran, R. Abrams, D. Schiff, E. Shaw (2011)
Validation of EORTC prognostic factors for adults with low-grade glioma: a report using intergroup 86-72-51.International journal of radiation oncology, biology, physics, 81 1
Linda Chang, D. Mcbride, B. Miller, M. Cornford, R. Booth, S. Buchthal, T. Ernst, D. Jenden (1995)
Localized In Vivo 1H Magnetic Resonance Spectroscopy and In Vitro Analyses of Heterogeneous Brain TumorsJournal of Neuroimaging, 5
G. Cairncross, D. MacDonald, S. Ludwin, D. Lee, T. Cascino, J. Buckner, D. Fulton, E. Dropcho, D. Stewart, C. Schold (1994)
Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 12 10
D. Hamstra, T. Chenevert, B. Moffat, T. Johnson, C. Meyer, S. Mukherji, D. Quint, S. Gebarski, Xiaoying Fan, C. Tsien, T. Lawrence, L. Junck, A. Rehemtulla, B. Ross (2005)
Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma.Proceedings of the National Academy of Sciences of the United States of America, 102 46
Tumor grade and molecular variants influence the survival of patients with glioma. The apparent diffusion coefficient (ADC) map is a non-invasive tool for evaluating the outcomes and response to therapy in glioma. In this study, we investigated the correlation between the tumor grade and prognostic biomarkers with the ADC in glioma patients. Eighty-two patients with supratentorial glioma were identified via analysis of surgical specimens and neuroradiological data. Using the World Health Organization grade, histological subtype, and molecular variants (1p/19q codeletion, isocitrate dehydrogenase 1/2 mutation, Ki-67 index, O6-methylguanine DNA methyltransferase, P53, and vascular endothelial growth factor immunoactivity) as prognostic biomarkers, we performed receiver operating characteristic analysis and multiple linear regression to assess the association between the magnetic resonance diffusion parameter and mean ADC and the prognostic factors of glioma pathology. Univariate analysis and multiple linear regression revealed inverse correlations between the ADC values and the tumor grade, oligodendrocytoma histology, and 1p/19q codeletion. A threshold mean ADC value could predict the 1p/19q chromosomal status in WHO II gliomas with 72 % sensitivity and 88 % specificity (area under the curve 0.82, 95 % confidence interval 0.68–0.97) and could distinguish low-grade glioma with low-risk factors from the high-risk group (P < 0.01). The mean ADC value could be used as a non-invasive tool to evaluate the prognosis of supratentorial glioma patients. A threshold mean ADC value could be used to predict the 1p/19q codeletion and to identify low-risk low-grade gliomas (LGGs). Lower ADC values are indicative of a favorable prognosis in LGGs.
Journal of Neuro-Oncology – Springer Journals
Published: May 30, 2014
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.